Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 02, 2024

SELL
$392.81 - $485.53 $152,410 - $188,385
-388 Reduced 47.55%
428 $200,000
Q1 2024

May 14, 2024

BUY
$407.69 - $446.08 $332,675 - $364,001
816 New
816 $341,000
Q2 2023

Aug 11, 2023

BUY
$314.42 - $351.91 $265,684 - $297,363
845 New
845 $297,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Fine Mark National Bank & Trust Portfolio

Follow Fine Mark National Bank & Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fine Mark National Bank & Trust, based on Form 13F filings with the SEC.

News

Stay updated on Fine Mark National Bank & Trust with notifications on news.